Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Christina Cunningham

Nurse Practitioner, Family Bettendorf, IA Nurse Practitioner

NPI 1003359308 CMS profile 10741539

2140 53Rd Ave, Bettendorf, IA 52722

Open in the dashboard

General payments

$4,111

202 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Christina Cunningham of Bettendorf, IA is reported in the CMS Open Payments database as having received $4,111 across 202 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,729 128
2024 General $1,357 73
2021 General $25 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Christina Cunningham
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Christina Cunningham were reported at $2,729. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Christina Cunningham Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $25 $124 $35–$379 $132
2022 $0 $141 $44–$430 $149
2023 $0 $154 $49–$476 $160
2024 $1,357 $165 $51–$504 $164
2025 $2,729 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Lilly USA, LLC $501 24 payments
  2. AbbVie, Inc. $432 24 payments
  3. Harmony Biosciences LLC $413 31 payments
  4. Eisai Inc. $374 19 payments
  5. Teva Pharmaceuticals USA, Inc. $330 11 payments
  6. SK Life Science, Inc. $287 9 payments
  7. Lundbeck LLC $267 8 payments
  8. Pfizer Inc. $236 16 payments
  9. Argenx US, Inc. $146 8 payments
  10. Novartis Pharmaceuticals Corporation $137 6 payments
  11. Other $988 46 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $3,847 199 payments
  2. Education $264 3 payments
Products named General payments · program years 2021–2025
  1. KISUNLA $411 18 payments
  2. Leqembi $374 19 payments
  3. QULIPTA $365 21 payments
  4. UBRELVY $340 19 payments
  5. VYEPTI $267 8 payments
  6. WAKIX Narcoplepsy $245 18 payments
  7. NURTEC ODT $236 16 payments
  8. ZAVZPRET $236 16 payments
  9. WAKIX Narcolepsy $168 13 payments
  10. KESIMPTA $137 6 payments
  11. Other $1,477 72 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 18 drugs

Part D claims

723

Median for Nurse Practitioner: 389

Drug cost

$116,914

Median for Nurse Practitioner: $21,885

Branded share of claims

12.4%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Qulipta Atogepant Brand 29 $42,257
Ubrelvy Ubrogepant Brand 17 $28,788
Nurtec Odt Rimegepant Sulfate Brand 12 $22,287
Emgality Pen Galcanezumab-Gnlm Brand 11 $10,270
Levetiracetam Generic 67 $1,941
Gabapentin Generic 73 $1,913
Memantine Hcl Generic 60 $1,738
Pyridostigmine Bromide Generic 14 $1,545
Donepezil Hcl Generic 173 $1,415
Amitriptyline Hcl Generic 74 $1,243

The 10 drugs with the highest cost, of 18 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 29 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
WAKIX
  • Harmony Biosciences LLC $245
$245 — —
KISUNLA
  • Lilly USA, LLC $88
$88 — —
Leqembi
  • Eisai Inc. $81
$81 — —
KESIMPTA
  • Novartis Pharmaceuticals Corporation $75
$75 — —
VYEPTI
  • Lundbeck LLC $72
$72 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 29 with Patron

Records

202 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Iowa

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record